波利维和泰嘉在冠心病治疗中的疗效和经济学

A comparative study of therapeutic efficacy and economic efficiency of Plavix and Techno in patients with coronary heart disease

目的对比分析应用波利维和泰嘉治疗冠心病的临床疗效和药物经济性,为日后临床用药提供依据。方法回顾分析从2012年6月到2013年6月期间我院收治的冠心病患者者66例。将66例患者按入院日期随机分为波利维组和泰嘉组。波利维患者(n=33)采用波利维治疗冠心病,泰嘉患者(n=33)采用泰嘉治疗。比较两组患者的治疗效果、术后12周血液学检查、不良不应和治疗费用。结果 1年内,波利维组的心血管不良事件(MACE)发生率效率为9.09%。泰嘉的心血管不良事件(MACE)发生率效率为12.12%,组患者的治疗效果无显著性差异(P>0.05)。术后12周血液学检查两组间无显著性差异(P>0.05)。部分患者发生血小板减少、皮疹、上腹部不适等不良反应,两组间的不良反应无显著性差异(P>0.05)。但在一年内,采用波利维控制病情平均需要(7258.62±980.50)元,而采用泰嘉控制病情只需要(4642.50±1020.56),组间有显著性差异(P<0.05)。结论进口药品波利维和国产的泰嘉在治疗冠心病的疗效上无差别,采用国产的泰嘉更为经济。

Objective To compare the therapeutic efficacy and economic efficiency of Plavix and Techno in patients with coronary heart disease, and to provide a basis for future clinical application. Methods A retrospective study was performed on 66 patients with coronary heart disease admitted to our hospital from June 2012 to June 2013.These patients were randomly divided into Plavix group and Techno group according to their admission dates. Patients in the Plavix（n =33） and Techno（n =33） groups were treated with Plavix and Techno, respectively. A hematological examination was performed and adverse reactions were recorded for each patient at 12 weeks after the treatment. Efficacy in both groups was compared in a 1-year follow-up. The cost for each treatment was also analyzed. Results The incidence rates of major adverse cardiac events in the Plavix and Techno groups were 9.09% and 12.12%, respectively,in the 1-year follow-up, and there was no significant difference between the two groups（P〉0.05）. In addition, no significant difference in results of the hematological examination was observed between the two groups at 12 weeks after the treatment（P〉0.05）. Although adverse reactions such as thrombocytopenia, rash, and abdominal discomfort were confirmed in some patients, there was no significant difference between the two groups（P〉0.05）. However, the 1-year cost of treatment in the Plavix group（7258.62 ±980.50）RMB was significantly higher than that in the Techno group（4642.50±1020.56）RMB（P〈0.05）. Conclusion There is no significant difference in efficacy between the imported drug Plavix and the domestic drug Techno in patients with coronary heart disease, whereas Techno has a much higher economic efficiency than Plavix, and thus should be widely used in the clinical treatment of coronary heart disease.